Signos Inc is categorized under Clinical Laboratory Instruments, Except Medical and Dental in , and active since 1984.
Signos Inc was established in 1984, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Clinical Laboratory Instruments, Except Medical and Dental business, which does work in the B2B market, and is classified as a Clinical Laboratory Instruments, Except Medical and Dental, under code number 333249 by the NAICS.
If you are seeking more information, feel free to contact Jose Roque Ramos at the company’s single location by writing to 73 Calle Santa Cruz # 210, , 00961 or by phoning (787) 780-2513. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Signos Inc |
| Contact Person: | Jose Roque Ramos |
| Address: | 73 Calle Santa Cruz # 210, , 00961 |
| Phone Number: | (787) 780-2513 |
| Annual Revenue (USD): | $100.000 to $499.999 |
| Founded: | 1984 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Clinical Laboratory Instruments, Except Medical and Dental |
| SIC Code: | 3821 |
| NAICS Code: | 333249 |
| Share This Business: |
Signos Inc was started in 1984 to provide professional Clinical Laboratory Instruments, Except Medical and Dental under the SIC code 3821 and NAICS code 333249. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact Jose Roque Ramos for inquiries that concern Signos Inc by calling the company number (787) 780-2513, as your correspondence is most welcome. Additionally, the physical location of the single location of Signos Inc can be found at the coordinates 18.39723,-66.148438 as well as the street address 73 Calle Santa Cruz # 210 in , 00961.
For its online presence, you may visit Signos Inc’s website at and engage with its social media outlets through on Twitter and on Facebook.